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Abstract
Currently, there is no adequate technology to detect early stage ovarian cancers. Most of the cancers in the ovary
are detected when the cancer has already metastasized to other parts of the body. As a result, ovarian cancer has
the highest mortality of all gynecologic cancers with a 5-year survival rate of 30% or less. Thus, there is an urgent
need to improve the current diagnostic techniques. Photoacoustic imaging (PAI) is an emerging modality with a
great potential to assist ultrasound for detecting ovarian cancer noninvasively. In this article, we report the first
study of coregistered ultrasound and PAI of 33 ex vivo human ovaries. An assessment of the photoacoustic
images has revealed light absorption distribution in the ovary, which is directly related to the vasculature distri-
bution and amount. Quantification of the light absorption levels in the ovary has indicated that, in the postmeno-
pausal group, malignant ovaries showed significantly higher light absorption than normal ones (P = .0237). For
these two groups, we have obtained a sensitivity of 83% and a specificity of 83%. This result suggests that
PAI is a promising modality for improving ultrasound diagnosis of ovarian cancer.
Translational Oncology (2011) 4, 29–37
Introduction
Cancer of the ovary has the lowest survival rate of all the gynecologic
cancers, with a 5-year survival rate of 30% or less [1,2]. Because of
the high mortality associated with ovarian cancer, most women with
a screening abnormality will undergo oophorectomy with at most
2% risk of having ovarian cancer [3]. With the current screening
and diagnostic abilities, we will continue to diagnose most women
with ovarian cancer (70%) at stage III or IV of the disease (wide-
spread intra-abdominal disease) and most of them will die of their
disease. By contrast, stage I cancers have a 5-year survival of 80%
to 90%. Technology capable of reliably diagnosing ovarian cancer
in earlier stages or before the development of invasive disease could
reduce the high mortality and the large economic impact of this dis-
ease, particularly in high-risk women. An even larger impact would
result from those women who could avoid surgery because they could
be assured that an ovarian mass was not cancer.
In 2002, two landmark studies [4,5] were published on the benefit
of prophylactic oophorectomy (PO), and it has become accepted as
the standard of care for women carrying the BRCA1 or 2 mutation.
Since then, PO has reduced the risk of ovarian cancer by more than
50% in these patients. In the absence of reliable methods for the early
detection of ovarian cancer, PO has been proposed as the most effec-
tive way to prevent this potentially lethal disease in this high-risk
group of women [6,7]. Although PO is effective in preventing breast
and ovarian cancer, there seems to be a higher mortality for premen-
opausal oophorectomy, and these high-risk women are not candi-
dates for hormone replacement therapy because of their increased
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risk of breast cancer. Thus, there is an urgent need for an alternative
to PO, which is the major rationale for developing better and more
sensitive tools to effectively evaluate the ovary.
Currently, there is no single test for ovarian cancer, and the com-
bination of the serum marker cancer antigen 125 screening (sensitiv-
ity of ∼50% [8–10]), transvaginal ultrasound (3% positive predictive
value [PPV] [11]), and pelvic examinations (sensitivity of <30% [9])
yields low PPV for routine screening. A recent review of imaging
technologies used for ovarian cancer surveillance concluded that cur-
rent imaging modalities are expensive and produce low-yield results
[12]. Computed tomographic (CT) scans have been studied exten-
sively for ovarian cancer detection, and multiple studies confirm that
CT has a sensitivity of 45% and a specificity of 85%. It is poor in the
detection of small metastases less than 2 cm. Magnetic resonance
imaging (MRI) has not been shown to have a significant advantage,
although it may be slightly more sensitive than CT. A 2003 publica-
tion [13] suggested that MRI was superior to CT for characterizing
malignant features of an ovarian mass and is often used when ultra-
sound is not diagnostic. However, the cost of MRI is high and is
usually used as secondary imaging method. Positron emission tomog-
raphy, using 18F-2-fluoro-2-deoxy-D-glucose as a tracer, can detect
malignant cancers with altered glucose metabolism and has been used
for the assessment of lymph node involvement [14], evaluation of
pretreatment staging and treatment response [14,15], and detection
of cancer metastases. It also holds promise in more accurate evalua-
tion of recurrent or residual cancers [16] than those morphologic
modalities. However, it has limited value in lesion localization in
early stages of ovarian cancer because of the difficulty in distinguish-
ing between the signal from early-stage cancers and the background
uptake signals coming from the normal tissue [17]. Thus, we have
not met the current need for better techniques to interrogate the
ovary to rule out cancer.
Photoacoustic imaging (PAI) is an emerging biomedical imaging
technique in which a short-pulsed laser beam penetrates diffusely
into a tissue sample [18–21]. The transient acoustic waves, or photo-
acoustic waves arising from thermoelastic expansion resulting from a
transient temperature rise (on the order of 10 mK), are then mea-
sured outside the sample by wide-band ultrasound transducers. The
acquired photoacoustic waves are used to reconstruct, at ultrasound
resolution, the light absorption distribution that reveals optical con-
trast, which is directly related to microvessel density of tumors or tu-
mor angiogenesis [22]. Angiogenesis is a key and very early process
for tumor growth and metastasis [22,23]. In addition, if two optical
wavelengths are used, the measured photoacoustic signals can be used
to reconstruct the distribution of tumor hypoxia, which is an impor-
tant and also very early indicator of tumor metabolism and therapeutic
response. These functional parameters are critical in the initial diag-
nosis of a tumor and the assessment of tumor response to treatment.
Because of intense light scattering in tissue, to date, pure optical meth-
ods require direct contact with the ovary, which necessitates an invasive
procedure to access the ovary [24,25]. PAI minimizes the deleterious
effects of intense light scattering by measuring ultrasonic waves gener-
ated from the tissue; therefore, it has great potential to noninvasively
reveal functional information about the ovary. Provided that enough
light fluency is delivered, the penetration depth of PAI is scalable with
ultrasound frequency. In the diagnostic frequency range of 3 to
8 MHz, the penetration depth in tissue can reach 3 cm using NIR
light [26], which is comparable with the penetration depth used in
conventional transvaginal ultrasound.
Coregistered ultrasound and PAI allows visualization of tumor
structure and functional changes simultaneously, which may poten-
tially reveal early tumor angiogenesis development that is not available
by ultrasound alone. The ability to detect early angiogenesis changes,
as well as tumor morphology changes in the ovary, using a noninvasive
imaging modality will greatly enhance the care for women.
In the past, we reported, for the first time, characterization results
of normal ex vivo ovarian tissue from pigs using a three-dimensional
coregistered ultrasound and PAI system [27,28]. The results showed
strong light absorption from highly vascularized corpora lutea and
low absorption from follicles, demonstrating that PAI is capable of
detecting vascularized structures in the ovary otherwise not visible
with ultrasound. In this article, we present the first imaging results
from ex vivo human ovaries consisting of normal, abnormal and ma-
lignant ovarian tissue. The ex vivo imaging assessment is a necessary
step toward translating this technology into in vivo clinical studies.
Our initial results indicate that PAI aided with ultrasound is capable
of differentiating normal ovaries from malignant ones based on light
absorption levels and distribution patterns.
Materials and Methods
Ovaries were extracted from patients undergoing oophorectomy at the
University of Connecticut Health Center. The patients were at risk for
ovarian cancer and were undergoing prophylactic surgery or had an
ovarian mass suggestive of a malignancy. The institutional review
board of the University of Connecticut Health Center approved this
study, and informed consent was obtained from all patients. Ovaries
were kept in a 0.9% wt/vol NaCl solution immediately after they were
excised and imaged within 24 hours after extraction. After imaging
experiments, the ovaries were fixed in formalin and returned to the
Pathology Department for histologic processing. For histologic evalu-
ation, the ovaries were cut into 5-mm blocks parallel to the imaging
plane, dehydrated with graded alcohol, embedded in paraffin, and sec-
tioned into 7-μm thickness using a paraffin microtome. Once the slides
that correspond to the imaged planes were identified, they were stained
using hematoxylin and eosin (H&E) and CD31 immunostaining.
A coregistered ultrasound and PAI system, designed and developed
in our laboratory, was used to image the ovaries. The details of the
system can be found in our earlier publications [27,28]. Briefly, the
system consists of a 1.75-dimensional ultrasound array capable of pro-
viding multiple ultrasound pulse-echo B-Scan images within 80- and
20-degree angles in the lateral and elevation directions, respectively,
which is suitable for ex vivo imaging of ovaries. The array has a nom-
inal center frequency of 5 MHz with 60% bandwidth. In PAI mode,
a tunable Ti-Sapphire laser (Symphotics TII, LS-2134; Symphotics,
Camarillo, CA), optically pumped with a Q-switched Nd:YAG laser
(Symphotics-TII, LS-2122), was used to illuminate the samples. The
laser, set to emit at 740 nm for this study, delivered 12-nanosecond
pulses at a rate of 15 Hz. The beam was diverged with a planoconcave
lens and homogenized by a circular profile engineered diffuser (ED1-
S20; ThorLabs, Newton, NJ) to produce a uniform illumination beam
on the sample of approximately 3 cm in diameter. The laser power was
limited to 4mJ/cm2, which is well below the ANSI limit [29]. The 1.75-
dimensional ultrasound array system is capable of switching from ultra-
sound pulse-echo mode to photoacoustic mode, providing coregistered
ultrasound and photoacoustic images. Both the ultrasound and photo-
acoustic images were reconstructed using a typical delay and sum algo-
rithm based on the transducer array geometry.
30 PAI and Ultrasound in Ovarian Cancer Detection Aguirre et al. Translational Oncology Vol. 4, No. 1, 2011
During imaging, the 1.75-dimensional transducer and the sample
were submerged in 0.9% NaCl solution. All the ovaries were placed
approximately in the same location inside the field of view, close to
the elevation focus of the transducer array in the axial direction and
centered in the azimuth direction. A diagram of the imaging setup is
shown in Figure 1. For most ovaries, several images were taken. In
the cases where the ovary was bigger than the illumination beam, the
images were acquired at different locations to cover most of it.
Ultrasound images were plotted on a gray scale, and photoacoustic
images were plotted using a color scale. In both cases, the brightest
colors indicate stronger signals. As a means to provide structural guid-
ance to the photoacoustic images, the obtained ultrasound and photo-
acoustic images were superimposed. In addition, to compare the PAI
results from all ovaries, we have ranked each ovary based on the de-
tected photoacoustic signal strength. This was accomplished by defin-
ing a parameter named average maximum RF signal (AMRFS), which
was computed for each imaging experiment and is given by:





where TxNumEl = 1280 is the number of elements in the ultrasound
transducer array and pi(t) is the measured photoacoustic signal at trans-
ducer element i. For the cases where several imaging experiments were
performed per ovary, an average of the AMRFS values was used to rank
each ovary. In that way, the averaged AMRFS parameter provides an
estimate of the overall level of light absorption for each ovary. Because
imaging was performed in a low absorbing medium, no ovarian tissue
and background boundary had to be defined to compute the AMRFS
from the measured signals. Nevertheless, transients from the front
face of the ultrasound transducer were removed before computation
of the parameter.
A two-sample t test was used to calculate significance for compar-
isons between groups. A difference with a P value of .05 was con-
sidered to be statistically significant. To estimate the sensitivity and
specificity, a threshold was retrospectively selected as the average of
AMRFS of all ovaries to separate most malignant ovaries from the
postmenopausal normal ovaries. False-negative results were malignant
ovaries with AMRFS lower than the threshold, and false-positive re-
sults were normal ovaries with AMRFS higher than the threshold.
The sensitivity and specificity were calculated as: Sensitivity = TP ×
100 / (TP + FN); specificity = TN × 100 / (TN + FP), where TP
is true-positive findings, TN is true-negative findings, FP is false-
positive findings, and FN is false-negative findings. In addition, the
positive predictive value was computed as PPV = TP × 100 / (TP + FP).
Results
A total of 33 ovaries from 24 patients (aged 38-83 years; mean, 58 years)
were imaged using the coregistered ultrasound and PAI system. All
premenopausal ovaries (n = 8) were diagnosed as normal, whereas post-
menopausal ovaries were diagnosed as normal (n = 6), abnormal (n =
11), and malignant (n = 8). The group of ovaries with abnormal diag-
nosis included ovaries with adenofibroma, necrotic fibrothecoma, fi-
broma, and ovaries from patients with carcinosarcoma or endometrial
cancer in the uterus or contralateral ovarian cancer. For the malignant
group, five of the samples were a portion of the whole ovary as part of
each ovary had to go for frozen section. Four of the five pieces were larger
than 4 cm and were included in the data analysis. One small piece of less
than 1 cm was removed from the analysis because of significant blood
loss in the sample. Therefore, it may not represent the hemoglobin con-
tent of the intact ovary. One ovary in the malignant group had few can-
cer cells on the surface which were likely transported from her 10-cm
pelvic carcinosarcomamass through bloodstream andwas removed from
data analysis. In addition, one necrotic fibrothecoma sample in the ab-
normal group consisted of dead tissue and was removed from the data
Figure 1. Experimental setup used for imaging ex vivo ovaries with the coregistered ultrasound and PAI system. Reproduced from
Aguirre et al. [28] with permission.
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analysis. A summary of the diagnosis of the remaining 30 ovaries is
given in Table 1.
Examples of Coregistered Ultrasound and PAI
Figure 2 (A and B) represents ultrasound and coregistered ultra-
sound and photoacoustic images of a 38-year-old high-risk woman
with enlarged ovaries found from clinical screening ultrasound (no. 5
in Table 1). The ultrasound image reveals the presence of several
antral follicles, which are typical of normal premenopausal ovaries.
In addition, the photoacoustic image indicates that most of the light
absorption takes place in the theca, which surrounds the antral fol-
licle and is rich in vasculature. The source of the light absorption is
the presence of blood in the theca, which volume depends on the
current stage of the development of the follicle. Histologic evaluation
of the sample revealed a normal premenopausal ovary (Figure 2C).
Immunostaining with CD31 revealed scattered microvessels in the
Table 1. Diagnostic and Measurement Summary of the Imaged Ovaries.
Patient No. Ovary Age, years Status Diagnostic Lowest AMRFS Mean AMRFS Peak AMRFS Mean AMRFS SD AMRFS
5 5 38 Pre Normal 2.33 3.11 3.84 2.95 0.58
6 6 44 1.99 1.99 1.99
8 8 46 2.05 2.40 2.63
10 11 47 2.68 2.93 3.40
17 20 47 1.89 3.34 4.04
17 21 47 3.54 3.62 3.71
21 28 41 2.12 2.61 3.22
22 29 43 2.23 3.57 6.21
1 1 58 Post Normal 2.19 2.19 2.20 2.39 0.50
4 4 53 1.84 1.84 1.84
12 13 64 2.16 2.35 2.66
13 15 72 1.94 1.99 2.04
20 27 59 2.83 3.18 3.37
24* 33 54 2.37 2.77 3.16
2 2 78 Post Carcinosarcoma in the uterus 1.85 1.85 1.85 2.82 0.90
3 3 58 Endometrial cancer 2.03 2.03 2.03
7 7 55 Endometrial cancer 3.14 4.31 5.48
9* 9 50 Endometrial cancer 1.92 1.99 2.05
9* 10 50 Endometrial cancer 2.04 2.05 2.07
14 16 52 Adenofibroma 1.92 3.45 6.99
16* 22 75 Ovarian cancer in other side 2.91 3.02 3.14
19* 25 60 Endometrial cancer 3.30 3.51 3.84
19* 26 60 Endometrial cancer 3.14 3.81 4.51
24* 32 54 Fibroma 1.96 2.21 2.58
15* 17 58 Post High-grade cancer on other ovary 4.42 5.08 6.21 3.55 0.89
15* 18 58 High-grade cancer 3.33 3.92 5.22
16* 19 75 Low-grade cancer 2.06 2.63 4.03
18 23 50 High-grade cancer 1.82 3.05 4.89
23* 30 55 Intermediate-grade cancer 1.93 2.99 4.61
23* 31 55 Intermediate-grade cancer 1.98 3.63 6.09
*Indicates patients whose both ovaries were studied.
Figure 2. Imaging of a normal premenopausal ovary. (A) Ultrasound image. (B) Coregistered ultrasound and photoacoustic image. (C)
H&E staining of the corresponding area (×1). (D) Immunostaining (CD31, ×100) revealing microvessels in the theca around the follicles
from the rectangular region indicated in B. White bar, 5 mm.
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theca around the follicles (Figure 2D). On the contrary, ultrasound
and photoacoustic images of the normal postmenopausal ovaries, in
general, were lacking follicles, and the light absorption across the en-
tire ovary was low.
An example of an abnormal ovary (no. 7 in Table 1) from a 55-year-
old postmenopausal patient with endometrial cancer is shown in
Figure 3. The photoacoustic image reveals a highly vascularized area
compared with the surrounding tissue. The H&E staining of the
corresponding region showed a high density of small vessels; however,
no malignant cells were found in the ovary. CD31 staining (Figure 3C)
revealed a cluster of randomly distributed small thick-walled irregular
arteries in the corresponding area. We hypothesize that the endome-
trial cancer may have increased the overall vascularity to the reproduc-
tive tract. Another scenario is that there was micrometastases to the
ovary not identified on the histologic section.
Coregistered images of a malignant ovary (no. 17 in Table 1) from
a 58-year old postmenopausal woman with bilateral ovarian cancers
at stage IIIC are shown in Figure 4. Images from two areas are shown
in Figure 4 (B and C ). High intraepithelial vascular areas compared
with the surrounding tissue are observed in the photoacoustic images.
The H&E staining of the corresponding regions showed high-grade
carcinoma (Figure 4, B1 and C1) and immunostaining with CD31
(Figure 4, B2 and C2) showed extensive thin-walled microvessels in
the corresponding regions.
Quantitative Analysis
We computed the average AMRFS value for each ovary. The scat-
ter plot in Figure 5 shows the average AMRFS values of all ovaries
from the four different groups. The results indicate the overall higher
light absorption levels in malignant postmenopausal ovaries than in
any other ovaries. Normal postmenopausal ovaries have, in general,
the lowest average AMRFS values. For these two groups of ovaries,
normal postmenopausal versus malignant postmenopausal, the sensi-
tivity and specificity are 83% (5/6) and 83% (5/6), respectively. The
PPV is 83% (5/6), which is a significant improvement to ultrasound
alone in current clinical practice. In the case of the abnormal post-
menopausal group, a wide variation of the average AMRFS is ob-
served among these ovaries. This can be explained by the fact that
this group consists of different types of abnormalities with different
amounts of vascular content. Similarly, normal ovaries in the pre-
menopausal group exhibit some degree of variation, which can be
attributed to different stages in the menstrual cycle at the time of
the surgery.
The mean AMRFS value for each postmenopausal group, along
with their standard deviation, is shown in Figure 6. A two-sample
t test showed statistical significance between normal (mean AMRFS =
2.39 ± 0.50, n = 6) and malignant (mean AMRFS = 3.55 ± 0.89, n =
6) postmenopausal ovaries (P = .0237). A t test between normal and
abnormal plus malignant (mean AMRFS = 3.10 ± 0.94, n = 16) post-
menopausal ovaries also showed statistical significance (P = .0368).
However, there was no statistical significance between normal and
abnormal ovaries (P = .2361) or between abnormal and malignant
(P = .1438) postmenopausal groups. Certainly, the sample sizes for all
groups are small in this pilot study. However, the results from the nor-
mal and malignant postmenopausal groups are promising and warrant
further investigation.
Although, no abnormal or malignant premenopausal ovaries were
imaged in this study, we have compared the normal premenopausal
ovaries with normal postmenopausal ones as shown in Figure 7. No
statistical significance between the two groups was found (P = .08).
Discussion
We have shown that PAI of normal ex vivo human ovaries provides
different light absorption distribution maps between premenopausal
and postmenopausal ovaries. Aided by morphologic information
from coregistered ultrasound images, the light absorption distribu-
tion in the photoacoustic images could improve the diagnosis of
an ovarian abnormality and potentially predict the risk of cancer.
When comparing the images from the normal premenopausal and
postmenopausal groups, the differences between the two groups
are clear, both in ultrasound and photoacoustic images. In the ultra-
sound images, several antral follicles are visible in the premenopausal
ovaries, whereas little to no follicular activity is observed in the post-
menopausal ovaries. Similarly, the photoacoustic images show areas
Figure 3. Imaging of an abnormal postmenopausal ovary from a patient with endometrial cancer. (A) Ultrasound image. (B) Coregistered
ultrasound and photoacoustic image. (C) Immunostaining (CD31) of the corresponding area (×1). (D) Immunostaining (×100) of the
highly vascularized area showing a cluster of small arteries from the rectangular region indicated in B. White bar, 5 mm.
Translational Oncology Vol. 4, No. 1, 2011 PAI and Ultrasound in Ovarian Cancer Detection Aguirre et al. 33
Figure 4. Imaging of a malignant postmenopausal ovary. (A) Coregistered ultrasound and photoacoustic images of two different loca-
tions are shown in B and C. (B1 and C1) H&E stains (×40) of the corresponding areas showing extensive high-grade tumors. (B2 and C2)
CD31 stains (×100) of the corresponding areas showing extensive thin-walled microvessels. White bar, 5 mm.
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of high light absorption around the follicles in the premenopausal
ovaries and low light absorption across the postmenopausal ovaries.
More specifically, when comparing the results among postmenopausal
subgroups (normal, abnormal, and malignant), marked differences
have been identified in the photoacoustic images. The light absorption
distribution from ovaries in the abnormal group varied more than in
the malignant ovaries, which showed more consistent results within
their group, suggesting this will be an important feature of malignancy
because of tumor angiogenesis. High light absorption from ovaries
in this group was observed mostly intraepithelial, corresponding to
epithelial-derived ovarian tumors, which constitute the predominant
and most lethal forms of the disease [30]. In general, abnormal and
malignant ovaries were much bigger than normal ones as observed
from the ultrasound images. Unfortunately, only normal premeno-
pausal ovaries where available for this study, partially because of the
somewhat rare occurrence of premenopausal ovarian cancer and par-
tially because of the high rate of prophylactic oophorectomy for women
at risk for ovarian cancer in our patient population; hence, no images
from premenopausal ovaries with different pathologic conditions
were available. These results demonstrate that PAI combined with
ultrasound could greatly improve the diagnosis of ovaries clinically,
especially in postmenopausal women where the ovaries are less active
and variations due to menstrual cycle changes are not present.
We further analyzed the results from the imaging experiments by
using the AMRFS parameter. The goal was to have, for a given ultra-
sound transducer and controlled imaging conditions, a means to com-
pare the light absorption levels from all ovaries. We chose to define this
parameter from the unprocessed received signals, instead of from the
formed images, to avoid limiting the scope of the parameter to just the
planes where the images were formed. Nevertheless, the considered sig-
nals were time-limited to avoid inclusion of transients from the front
face of the ultrasound transducer. Performing the study in ex vivo ova-
ries presented both advantages and disadvantages. We had control over
the imaging conditions, such as using orthogonal illumination, non-
absorbing background (both not available in vivo) to minimize result
interpretation errors. However, by extracting the ovaries, their blood
content was reduced because of bleeding, which directly affected the
measurements. This was true in all the studied ovaries; however, in
most malignant cases, the ovaries had to be divided and a portion
submitted immediately for frozen-section pathologic evaluation of tu-
mor receptors and tumor banking. This further accentuated the blood
loss in the samples imaged. Nevertheless, the results showed that the
malignant group has the highest AMRFS values. It is likely that the
in vivo vascular contrast of the malignant group would be higher
than that reported in this ex vivo study and thus be more sensitive
and specific.
A limitation of the photoacoustic technique is that it provides rel-
ative optical absorption changes rather than quantitative tissue ab-
sorption coefficients. In an effort to correlate the results obtained
using the AMRFS to quantitative absorption coefficients of the ovaries,
we used a diffuse optical tomography system [31,32] to image the ova-
ries immediately after the photoacoustic experiments. Diffused light
imaging has limited resolution; however, it can reconstruct target op-
tical absorption coefficient μa within 60% to 100% accuracy [32,33].
Figure 5. Scatter plot of the measured AMRFS values of four
groups. The vertical axis is the AMRFS, and the horizontal axis
presents four groups. A threshold is chosen as the average of
all the AMRFS measurements of all ovaries. For the postmeno-
pausal group, the sensitivity and specificity between normal and
malignant ovaries is 83%.
Figure 6. Statistics of AMRFS of all subgroups of postmenopausal
ovaries. Statistical significancebetweennormal andmalignant ovaries
is shown, as well as between normal and abnormal and malignant.
Figure 7. Statistics of AMRFS of all normal ovaries.
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The overall reconstructed μa for each group of ovaries showed similar
trends as those obtained by computing the AMRFS parameter from
photoacoustic data. The malignant postmenopausal ovaries had the
highest μa (0.153 ± 0.037/cm considering whole ovaries only), whereas
the normal postmenopausal ovaries had the lowest one (0.069 ±
0.006/cm). Abnormal postmenopausal ovaries again exhibit variable
values of μa (0.092 ± 0.027/cm) depending on the pathologic condi-
tion. The linear regression curve of the average AMRFS versus mea-
sured absorption coefficient of the 24 whole ovaries imaged with the
diffuse optical tomography system was obtained from least square so-
lutions and is shown in Figure 8. The computed correlation coefficient
reflecting the goodness of fit was 0.59 with P = .0023 at a confidence
level of 0.05. Note that diffuse optical tomography is suitable for im-
aging the entire ovary because the diffused light probes a target from
all directions and is sensitive to blood loss at surgical interfaces.
A limitation of the study was the lack of information regarding the
menstrual cycle stage at the time of prophylactic oophorectomy on
premenopausal patients. Although the number of ovaries in this group
was small, variations in AMRFS levels among the ovaries are evident
and most likely due to differences in the menstrual cycle or due to
differences in the age of the patient. The overall light absorption level
obtained from this group was higher than that from the normal post-
menopausal group. This was expected because postmenopausal ovaries
are less active than premenopausal ones, which have highly vascular-
ized structures such as corpus luteum and corpus hemorrhagicum.
On the basis of our initial results reported in this study, we believe
that a combination of light absorption distribution and quantifica-
tion from photoacoustic images could be used to noninvasively screen
postmenopausal women in vivo and hence improve the ultrasound di-
agnosis of ovarian cancer. Implementing this technique requires a co-
registered ultrasound and photoacoustic probe that can image the
ovaries transvaginally as the standard transvaginal ultrasound. Some
potential issues in an in vivo setup are the effect of background tissue
on light delivery and acoustic attenuation. Not only both of these fac-
tors could affect image quality, but their variability in patients would
also have to be considered when estimating the light absorption level
of the ovaries. However, advantages of an in vivo imaging approach are
the possibility of measuring the oxygen saturation using two wave-
lengths and the absence of blood loss due to surgical intervention.
From the oxygen saturation measurements, an estimation of tumor
hypoxia, which is an important indicator of tumor metabolism and
therapeutic response, could be obtained. The biggest advantage, how-
ever, is the noninvasive nature of this technology.
Summary
A total of 33 ex vivo human ovaries have been studied. Results have
shown that PAI of the ovaries provides light absorption distributions
that depend on the pathologic condition of the ovary in the post-
menopausal group. By comparing the light absorption levels of the
ovaries, PAI was capable of diagnosing ovarian cancer from normal
postmenopausal ovaries with a sensitivity of 83% and specificity of
83%. Combined with coregistered ultrasound, PAI can potentially
improve the current diagnosis of ovarian cancer in postmenopausal
women. For premenopausal normal ovaries, our limited data showed
no statistically significant difference in light absorption level when
compared with normal postmenopausal ovaries. However, no abnor-
mal or malignant premenopausal ovaries were available in this study.
The most important finding is that this approach can be easily com-
bined with ultrasound for better performance than ultrasound alone.
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